Biomanufacturing And Gene Therapies Will Expand Precision Medicine

Published
20 Jan 25
Updated
21 Aug 25
AnalystConsensusTarget's Fair Value
NOK 29.00
0.7% undervalued intrinsic discount
21 Aug
NOK 28.80
Loading
1Y
32.1%
7D
14.3%

Author's Valuation

NOK 29.0

0.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on15 Aug 25
Fair value Increased 66%

The significant increase in consensus analyst price target for ArcticZymes Technologies is primarily driven by notably higher forecasts for revenue growth and a rising future P/E multiple, resulting in an upward revision from NOK17.50 to NOK24.50. What's in the News Launched M-SAN HQ GMP, a new GMP-grade nuclease tailored for viral vector manufacturing, enabling high activity in physiological salt conditions and improving DNA removal without harsh buffers.